415 related articles for article (PubMed ID: 19250189)
1. 17beta-hydroxysteroid dehydrogenases in human breast cancer.
Nagasaki S; Miki Y; Akahira J; Suzuki T; Sasano H
Ann N Y Acad Sci; 2009 Feb; 1155():25-32. PubMed ID: 19250189
[TBL] [Abstract][Full Text] [Related]
2. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
3. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Smuc T; Rizner TL
Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
[TBL] [Abstract][Full Text] [Related]
4. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Aka JA; Mazumdar M; Lin SX
Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
[TBL] [Abstract][Full Text] [Related]
5. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
6. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
[TBL] [Abstract][Full Text] [Related]
7. Steroid metabolism in breast cancer.
Foster PA
Minerva Endocrinol; 2008 Mar; 33(1):27-37. PubMed ID: 18277377
[TBL] [Abstract][Full Text] [Related]
8. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.
Ito K; Utsunomiya H; Suzuki T; Saitou S; Akahira J; Okamura K; Yaegashi N; Sasano H
Mol Cell Endocrinol; 2006 Mar; 248(1-2):136-40. PubMed ID: 16406263
[TBL] [Abstract][Full Text] [Related]
9. New development in intracrinology of breast carcinoma.
Sasano H; Suzuki T; Nakata T; Moriya T
Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
[TBL] [Abstract][Full Text] [Related]
10. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
11. Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study.
Song D; Liu G; Luu-The V; Zhao D; Wang L; Zhang H; Xueling G; Li S; Désy L; Labrie F; Pelletier G
J Steroid Biochem Mol Biol; 2006 Oct; 101(2-3):136-44. PubMed ID: 16930994
[TBL] [Abstract][Full Text] [Related]
12. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
Brooks JD; Thompson LU
J Steroid Biochem Mol Biol; 2005 Apr; 94(5):461-7. PubMed ID: 15876411
[TBL] [Abstract][Full Text] [Related]
13. Progestins and breast cancer.
Pasqualini JR
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():32-41. PubMed ID: 17943537
[TBL] [Abstract][Full Text] [Related]
14. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells.
Gonzalez A; Cos S; Martinez-Campa C; Alonso-Gonzalez C; Sanchez-Mateos S; Mediavilla MD; Sanchez-Barcelo EJ
J Pineal Res; 2008 Aug; 45(1):86-92. PubMed ID: 18298468
[TBL] [Abstract][Full Text] [Related]
15. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
Day JM; Tutill HJ; Purohit A; Reed MJ
Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
[TBL] [Abstract][Full Text] [Related]
16. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
Marchais-Oberwinkler S; Henn C; Möller G; Klein T; Negri M; Oster A; Spadaro A; Werth R; Wetzel M; Xu K; Frotscher M; Hartmann RW; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):66-82. PubMed ID: 21193039
[TBL] [Abstract][Full Text] [Related]
17. 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
Nagasaki S; Suzuki T; Miki Y; Akahira J; Kitada K; Ishida T; Handa H; Ohuchi N; Sasano H
Cancer Res; 2009 Feb; 69(4):1392-9. PubMed ID: 19190350
[TBL] [Abstract][Full Text] [Related]
18. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Suzuki T; Moriya T; Ariga N; Kaneko C; Kanazawa M; Sasano H
Br J Cancer; 2000 Feb; 82(3):518-23. PubMed ID: 10682658
[TBL] [Abstract][Full Text] [Related]
19. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
Jansson AK; Gunnarsson C; Cohen M; Sivik T; Stål O
Cancer Res; 2006 Dec; 66(23):11471-7. PubMed ID: 17145895
[TBL] [Abstract][Full Text] [Related]
20. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
Liu ZJ; Lee WJ; Zhu BT
Cancer Res; 2005 Jul; 65(13):5802-11. PubMed ID: 15994956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
